ISRG

Bias

UNDERWEIGHT

Horizon

Long-term

Key risk

Competitor data from J&J or Medtronic showing rapid commercial traction would pressure the stock. The death cross and the $470 resistance are real technical hurdles — we need volume to break through. And macro caution (UBS warning, Goldman’s AI payoff question) could keep a lid on the multiple. But the fundamental thesis is intact: recurring revenue, growing procedures, AI tailwinds, and a stock that’s already corrected ~20% from its highs. The bear case is already priced in; the bull case starts from here.

Catalyst watch

ISRG is in a sustained downtrend with price trading decisively below both its 50-day ($470) and 200-day ($499) SMAs — a classic bearish structure with no bullish crossover signals present.